Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
Authors:
- Laura RidolfiLaura Ridolfi
- Massimiliano PetriniMassimiliano Petrini
- Anna Maria GranatoAGAnna Maria Granato
- Giusy GentilcoreGGGiusy Gentilcore
- Ester SimeoneESEster Simeone
- Paolo Antonio AsciertoPAPaolo Antonio Ascierto
- Elena PancisiEPElena Pancisi
- Valentina AncaraniVAValentina Ancarani
- Laura FiammenghiLFLaura Fiammenghi
- Massimo GuidoboniMGMassimo Guidoboni
- Francesco de RosaFRFrancesco de Rosa
- Linda ValmorriLVLinda Valmorri
Open Access
- 1 January 2013
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 135
Abstract
In cancer immunotherapy, dendritic cells (DCs) play a fundamental role in the dialog between innate and adaptive immune response, but several immunosuppressive mechanisms remain to be overcome. For example, a high number of CD4+CD25++Foxp3+ regulatory T-cells (Foxp3+Tregs) have been observed in the peripheral blood and tumor microenvironment of cancer patients. On the basis of this, we conducted a study on DC-based vaccination in advanced melanoma, adding low-dose temozolomide to obtain lymphodepletion. Twenty-one patients were entered onto our vaccination protocol using autologous DCs pulsed with autologous tumor lysate and keyhole limpet hemocyanin. Patients received low-dose temozolomide before vaccination and 5 days of low-dose interleukin-2 (IL-2) after vaccination. Circulating Foxp3+Tregs were evaluated before and after temozolomide, and after IL-2. Among the 17 evaluable patients we observed 1 partial response (PR), 6 stable disease (SD) and 10 progressive disease (PD). The disease control rate (PR+SD = DCR) was 41% and median overall survival was 10 months. Temozolomide reduced circulating Foxp3+Treg cells in all patients. A statistically significant reduction of 60% was observed in Foxp3+Tregs after the first cycle, whereas the absolute lymphocyte count decreased by only 14%. Conversely, IL-2 increased Foxp3+Treg cell count by 75.4%. Of note the effect of this cytokine, albeit not statistically significant, on the DCR subgroup led to a further 33.8% reduction in Foxp3+Treg cells. Our results suggest that the combined immunological therapy, at least as far as the DCR subgroup is concerned, effectively reduced the number of Foxp3+Treg cells, which exerted a blunting effect on the growth-stimulating effect of IL-2. However, this regimen, with its current modality, would not seem to be capable of improving clinical outcome.Keywords
This publication has 29 references indexed in Scilit:
- Dendritic cell-based vaccine in advanced melanomaMelanoma Research, 2011
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011
- Molecular Profiling of Melanoma and the Evolution of Patient-Specific TherapySeminars in Oncology, 2011
- Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanomaJournal of Translational Medicine, 2010
- Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatmentJournal of Translational Medicine, 2010
- Immunotherapy for Melanoma: Current Status and PerspectivesJournal of Immunotherapy, 2010
- Indoleamine 2,3-dioxygenase–expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cellsBlood, 2009
- Dendritic cells: Understanding immunogenicityEuropean Journal of Immunology, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic ImplicationsJournal of Clinical Oncology, 2004